uniQure N.V. (QURE)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Matthew C. Kapusta
Employees:
500
1-339-970-7000

uniQure N.V. engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in clinical study for Huntington's disease.

Data derived from most recent annual or quarterly report
Market Cap 334.882 Million Shares Outstanding47.704 Million Avg 30-day Volume 901.791 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.88
Price to Revenue4.8714 Debt to Equity0.3645 EBITDA-167.315 Million
Price to Book Value1.5434 Operating Margin-153.8882 Enterprise Value45.501 Million
Current Ratio11.074 EPS Growth-0.642 Quick Ratio10.696
1 Yr BETA 1.1845 52-week High/Low 28.26 / 5.49 Profit Margin-166.8298
Operating Cash Flow Growth-85.7723 Free Cash Flow to Firm (FCFF) TTM 122.441 Million Free Cash Flow to Equity (FCFE) TTM-128.764 Million
Altman Z-Score-0.1493
Earnings Report2024-02-27
View SEC Filings from QURE instead.

View recent insider trading info

uniQure N.V. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding QURE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding QURE

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 3: filed on 2023-10-02 by ABI-SAAB WALID
  • 4: filed on 2023-09-20 by DOLMETSCH RICARDO
  • 4: filed on 2023-07-12 by CALOZ PIERRE
  • 4: filed on 2023-06-20 by JACQUES RACHELLE SUZANNE
  • 4: filed on 2023-06-20 by SOTEROPOULOS PAULA
  • 4: filed on 2023-06-20 by POST LEONARD E
  • 4: filed on 2023-06-20 by KAYE JACK
  • 4: filed on 2023-06-20 by GUT ROBERT
  • 4: filed on 2023-06-20 by CALOZ PIERRE
  • 4: filed on 2023-06-20 by KLEMT CHRISTIAN

    • Events (8k)

  • 8-K: filed on 2023-11-17:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-11-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-05:
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-22:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-16:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-16:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-05:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-02-27:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

  • 144: filed on 2023-07-10:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ABI-SAAB WALID CHIEF MEDICAL OFFICER

    • Officer
    		 67,200 2023-09-27 1

    DOLMETSCH RICARDO PRESIDENT, R&D

    • Officer
    		 163,404 2023-09-18 6

    CALOZ PIERRE CHIEF OPERATING OFFICER

    • Officer
    		 95,098 2023-07-10 7

    KLEMT CHRISTIAN CHIEF FINANCIAL OFFICER

    • Officer
    		 132,854 2023-06-16 6

    POST LEONARD E

    • Director
    		 18,221 2023-06-13 2

    KAYE JACK

    • Director
    		 34,119 2023-06-13 2

    MEEK DAVID D.

    • Director
    		 22,481 2023-06-13 2

    BALACHANDRAN MADHAVAN

    • Director
    		 25,990 2023-06-13 2

    SOTEROPOULOS PAULA

    • Director
    		 22,423 2023-06-13 5

    GUT ROBERT

    • Director
    		 47,669 2023-06-13 2

    SPRINGHORN JEREMY P.

    • Director
    		 25,987 2023-06-13 2

    JACQUES RACHELLE SUZANNE

    • Director
    		 16,629 2023-06-13 2

    POTTS JEANNETTE SEE REMARKS

    • Officer
    		 0 2023-06-13 2

    KAPUSTA MATTHEW C CEO, MANAGING DIRECTOR

    • Officer
    • Director
    		 468,743 2023-03-07 5

    KUTA ALEXANDER EDWARD III EXECUTIVE VP, OPERATIONS

    • Officer
    		 90,381 2023-03-07 4

    ASTLEY-SPARKE PHILIP

    • Director
    		 9,946 2021-03-02 0

    VAN DEVENTER SANDER EVP, RESEARCH & PRODUCT DEV.

    • Officer
    		 71,458 2020-02-27 0

    SCHAFFER DAVID

    • Director
    		 46,978 2020-02-27 0

    MCMILLAN SCOTT T. CHIEF OPERATING OFFICER

    • Officer
    		 20,432 2019-01-28 0

    ZELENKOFSKE STEVEN CHIEF MEDICAL OFFICER

    • Officer
    		 159,458 2018-06-06 0

    FORUNIQURE B.V.

    FORBION 1 MANAGEMENT B.V.

    • 10% Owner
    		 4,376,883 2018-04-23 0

    CANTOR MARIA E SVP, INVESTOR REL. & COMM.

    • Officer
    		 92,439 2018-01-26 0

    FIRUTA PAUL E CHIEF COMMERCIAL OFFICER

    • Officer
    		 93,817 2018-01-26 0

    GAREN JONATHAN CHIEF BUSINESS OFFICER

    • Officer
    		 93,638 2018-01-26 0

    PETRY HARALD CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2017-06-28 0

    LEWIS WILLIAM

    • Director
    		 0 2017-01-27 0

    KESON-BROOKES MAIKEN GENERAL COUNSEL

    • Officer
    		 0 2017-01-27 0

    MEYER CHRISTIAN CHIEF MEDICAL OFFICER

    • Officer
    		 0 2017-01-27 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    UNIQURE NV QURE 2023-11-28 12:45:04 UTC 4.9008 0.4192 3800000
    UNIQURE NV QURE 2023-11-27 22:15:04 UTC 4.8947 0.4253 3900000
    UNIQURE NV QURE 2023-11-27 21:45:04 UTC 4.8947 0.4253 3900000
    UNIQURE NV QURE 2023-11-27 21:15:03 UTC 4.8947 0.4253 3900000
    UNIQURE NV QURE 2023-11-27 20:45:04 UTC 4.8947 0.4253 3900000
    UNIQURE NV QURE 2023-11-27 20:15:05 UTC 4.8864 0.4336 3900000
    UNIQURE NV QURE 2023-11-27 19:45:04 UTC 4.8864 0.4336 3900000
    UNIQURE NV QURE 2023-11-27 19:15:04 UTC 4.8864 0.4336 3900000
    UNIQURE NV QURE 2023-11-27 18:45:05 UTC 4.8864 0.4336 3900000
    UNIQURE NV QURE 2023-11-27 18:15:03 UTC 4.8864 0.4336 3900000
    UNIQURE NV QURE 2023-11-27 17:45:04 UTC 4.8864 0.4336 3900000
    UNIQURE NV QURE 2023-11-27 17:15:03 UTC 4.8864 0.4336 3900000
    UNIQURE NV QURE 2023-11-27 16:45:04 UTC 4.8864 0.4336 3900000
    UNIQURE NV QURE 2023-11-27 16:15:03 UTC 4.8864 0.4336 3900000
    UNIQURE NV QURE 2023-11-27 15:45:04 UTC 4.8864 0.4336 3900000
    UNIQURE NV QURE 2023-11-27 15:15:03 UTC 4.8864 0.4336 3900000
    UNIQURE NV QURE 2023-11-27 14:45:03 UTC 4.8864 0.4336 3900000
    UNIQURE NV QURE 2023-11-27 14:15:04 UTC 4.8864 0.4336 3900000
    UNIQURE NV QURE 2023-11-27 13:45:04 UTC 4.8373 0.4827 3900000
    UNIQURE NV QURE 2023-11-27 13:15:04 UTC 4.8373 0.4827 3800000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments